drugset / Trial / NCT04801966
Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study
NaSingle-groupOpen-labelTreatment
Summary
This study is looking at outcomes in people with advanced cancers who have exhausted standard treatment options and are accessing off indication or unregistered drugs or combinations of drugs through compassionate access from the manufacturer.
Timeline
- Start
- 2021-09-23
- Primary completion
- 2022-12-30
- Completion
- 2022-12-30
Outcome
Outcome not reported
Stopped (Enrollment): “low recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 150 mg | — |
| Subject | Alpelisib | Small molecule | 300 mg | — |
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Binimetinib | Small molecule | 45 mg | — |
| Subject | Cobimetinib | Small molecule | 60 mg | — |
| Subject | Dabrafenib | Small molecule | 150 mg | — |
| Subject | Encorafenib | Small molecule | 450 mg | — |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |
| Subject | Olaparib | Small molecule | 300 mg | — |
| Subject | Palbociclib | Small molecule | 125 mg | — |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Ribociclib | Small molecule | 600 mg | — |
| Subject | Talazoparib | Small molecule | 1 mg | — |
| Subject | Trametinib | Small molecule | 2 mg | — |
| Subject | Vemurafenib | Small molecule | 960 mg | — |